


FIGURE 3A. MANAGEMENT OF MODERATE TO SEVERE SUSPECT, PROBABLE, OR CONFIRMED COVID-19

NOVEMBER 7, 2020



FOOTNOTES

^aOxygen saturations cut off of <93% was the consensus of pulmonologist and infectious disease specialists.

^bNeed informed consent BEFORE using COVID-19 investigational drugs & interventions in trials or compassionate use.

^cInvestigational Drugs For Moderate COVID-19

- Favipiravir - Remdesivir - Convalescent plasma

^dInvestigational Drugs For Severe and Critical COVID-19

- Remdesivir 200 mg IV loading dose then 100 mg IV OD, infused over 30 mins for 5-10 days
- Convalescent plasma - Immunomodulator (Tocilizumab)

^eImprovement of clinical status

- No fever or use of antipyretic for at least 3 days
- Respiratory symptoms reduced significantly
- CXR (if available) shows significant improvement